Physician profile
Daniel T Richards
NPI 1649455403
$1,431.89
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $65.06 · 2021: $473 · 2022: $87.33 · 2023: $25.82 · 2024: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $154 · Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $154.05 |
| Food and Beverage | $124.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conformis, INC. | $448.89 | 2020-2021 | |
| Medacta USA, INC. | $417.63 | 2019 | |
| Zimmer Biomet Holdings, INC. | $178.29 | 2019-2024 | Persona |
| Stryker Corporation | $128.65 | 2019-2024 | Aequalis Perform Reversed |
| Endo Pharmaceuticals INC. | $45.63 | 2020-2021 | |
| Smith+Nephew, INC. | $41.35 | 2022 | |
| Hologic Sales and Service, LLC | $37.34 | 2024 | Thinprep 2000 Processor |
| Pacira Therapeutics, INC. | $27.82 | 2019 | |
| Anika Therapeutics, INC. | $25.82 | 2023 | Wristmotion, Speedspiral, Atlas |
| Abbvie INC. | $24.50 | 2022 | |
| Vericel Corporation | $23.45 | 2019 | |
| Welch Allyn | $19.16 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.